Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
9/4/2024 | $52.00 | Outperform → Neutral | Wedbush | |
3/25/2024 | $50.00 → $75.00 | Hold → Buy | Loop Capital | |
1/18/2024 | $41.00 → $61.00 | Neutral → Overweight | Piper Sandler | |
12/8/2023 | $45.00 | Outperform → Market Perform | TD Cowen | |
11/20/2023 | $25.00 | Neutral | JP Morgan | |
9/28/2023 | $33.00 | Overweight | Piper Sandler | |
8/3/2023 | $36.00 → $31.00 | Buy → Neutral | BofA Securities | |
5/4/2023 | $30.00 | Equal Weight → Overweight | Wells Fargo |
– Expects to use Term Loan B proceeds to fund the proposed acquisition of Mattress Firm LEXINGTON, Ky., Oct. 4, 2024 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX, ", Company", or ", Tempur Sealy", ))) today announced that it has successfully priced its previously announced senior secured Term Loan B facility in an aggregate principal amount of $1.6 billion (the "Term Loan B"). The Term Loan B will mature seven years after the date of closing of the Term Loan B, which is expected to occur in the next few weeks. The Term Loan B priced at SOFR + 250 bps with an OID of 99.5. Tempur Sealy intends to use the proceeds from the Term Loan B, together with cash available and proceeds f
– Company Argues FTC is Violating Constitutional Protections LEXINGTON, Ky., Oct. 4, 2024 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX, ", Company", or ", Tempur Sealy", ))) today filed a complaint in the United States District Court for the Southern District of Texas (the "Southern District of Texas") seeking an injunction against the Federal Trade Commission's ("FTC") administrative proceeding challenging the Company's merger with Mattress Firm Group Inc. ("Mattress Firm"). The action filed today asks the Southern District of Texas to prevent the FTC from challenging the merger via its own separate administrative proceeding in addition to the federal court proceeding that
– Expects to use proceeds to fund the proposed acquisition of Mattress Firm – Anticipates drawing on the loan concurrent with closing the proposed acquisition LEXINGTON, Ky., Sept. 23, 2024 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX, ", Company", or ", Tempur Sealy", ))) today announced that it is launching a proposed senior secured Term Loan B facility in an aggregate principal amount of up to $1.6 billion (the "Term Loan B"). The Term Loan B will mature seven years after the date of closing. Tempur Sealy intends to use the proceeds from the Term Loan B, together with cash available and proceeds from other debt, to fund the cash consideration for the previously announce
SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
SC 13G/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
Wedbush analyst Seth Basham reiterates Tempur Sealy Intl (NYSE:TPX) with a Outperform and maintains $55 price target.
In the last three months, 7 analysts have published ratings on Tempur Sealy Intl (NYSE:TPX), offering a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 5 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 3 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 0 0 0 Analysts have recently evaluated Tempur Sealy Intl and provided 12-month price targets. The average target is $64.0, accompanied by a high estimate of $66.00 and a low estimate of $58.00. Experiencing a
LEXINGTON, Ky., Aug. 6, 2024 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX, ", Company", or ", Tempur Sealy", ))) today announced that its Board of Directors has declared a third quarter cash dividend on its common stock of $0.13 per share. The dividend is payable on August 29, 2024, to shareholders of record as of August 15, 2024. About Tempur Sealy International, Inc. Tempur Sealy is committed to improving the sleep of more people, every night, all around the world. As a leading designer, manufacturer, distributor and retailer of bedding products worldwide, we know how crucial a good night of sleep is to overall health and wellness. Utilizing over a century of knowledge and i
- Consolidated Sales Decreased 3%, Direct Channel Sales Increased 1%- Consolidated Gross Margins Expanded 2.2% to 44.9%- Strong EPS Growth of 15% and Adjusted EPS(1) Growth of 9% LEXINGTON, Ky., Aug. 6, 2024 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX) announced financial results for the second quarter ended June 30, 2024 and revised financial guidance for the full year 2024. SECOND QUARTER 2024 FINANCIAL SUMMARY Total net sales decreased 2.8% to $1,233.6 million as compared to $1,269.7 million in the second quarter of 2023, with a decrease of 3.8% in the North America business segment and consistent sales in the International business segment. On a constant currency basis(1)
LEXINGTON, Ky., July 15, 2024 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE:TPX) will release its financial results for the second quarter ended June 30, 2024, before the NYSE opening of regular trading on Tuesday, August 6, 2024. The Company will hold a conference call at 8:00 a.m. Eastern Time. The call will be webcast and can be accessed on the Company's investor relations website at investor.tempursealy.com. After the conference call, a webcast replay will remain available on the website for 30 days. About the Company Tempur Sealy is committed to improving the sleep of more people, every night, all around the world. As a leading designer, manufacturer, distributor, and retailer
Wedbush downgraded Tempur Sealy Int'l from Outperform to Neutral and set a new price target of $52.00
Loop Capital upgraded Tempur Sealy Int'l from Hold to Buy and set a new price target of $75.00 from $50.00 previously
Piper Sandler upgraded Tempur Sealy Int'l from Neutral to Overweight and set a new price target of $61.00 from $41.00 previously
PACS Group, Inc. (NYSE:PACS) ("PACS" or the "Company") announced today that Evelyn Dilsaver has been appointed to serve as a member of its Board of Directors. "We're thrilled to have Evelyn join our board," said Jason Murray, PACS Chairman and CEO. "She has great experience as an accounting and finance professional, not to mention her work on the boards of several other public companies. She'll bring added perspective and expertise to the board as we work to guide PACS going forward." "I'm excited to join the PACS Board and assist the company in continuing its mission to provide quality skilled nursing care. I look forward to great things ahead for the company," added Ms. Dilsaver. Ms.
Mr. Burgess will be responsible for leading Cerevel's business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Paul Burgess as chief business development and strategic operations officer, effective June 20, 2023. "I am so pleased to welcome Paul to Cerevel as our chief business development and strategic operations officer, with his proven track record of success in the biotech and pharmaceutical industry," said Ron Renaud, president and chie
Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel Dr. Altschuller to become CFO effective May 15, 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Susan Altschuller, Ph.D. as chief financial officer (CFO), effective May 15, 2023. "We are excited to welcome Susan to Cerevel, as she brings a breadth of experience leading biopharmaceutical companies by leveraging her strategic understanding, f
8-K - TEMPUR SEALY INTERNATIONAL, INC. (0001206264) (Filer)
8-K - TEMPUR SEALY INTERNATIONAL, INC. (0001206264) (Filer)
8-K - TEMPUR SEALY INTERNATIONAL, INC. (0001206264) (Filer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)